Date of report 26 Apr 2022
Reported case interaction between
Ritonavir and APIXABAN

FLS Science

Drugs suspected to be involved in the DDI

Perpetrator
Ritonavir
Daily Dose
100 (mg)
Dose adjustment performed
No
Administration Route
Oral
Start date
Unknown
End date
Ongoing
Victim
APIXABAN
Daily Dose
5 (mg)
Dose adjustment performed
No
Administration Route
Oral
Start date
Unknown
End date
Ongoing

Complete list of drugs taken by the patient

Antiretroviral treatment
Darunavir (with Ritonavir or Cobicistat)
Emtricitabine/Tenofovir-DF
Complete list of all comedications taken by the patient, included that involved in the DDI

Llevetiracetam 1000 mg BID, Lamotrigine 75 mg BID

Clinical case description

Gender
Male
Age
73
eGFR (mL/min)
>60
Liver function impairment
No
Description

A 73-year-old male treated with ritonavir boosted darunavir was initially started on warfarin for the treatment of a newly diagnosed non-valvular atrial fibrillation. Due to the difficulty in normalizing INR while receiving warfarin treatment and due to bleeding episodes that occurred while the patient was receiving this medication, it was decided to switch warfarin to the direct oral anticoagulant apixaban. The patient received apixaban at a dose of 2.5 mg twice daily together with darunavir/ritonavir and did not present adverse effects including bleeding or recurrent thrombus. The present case has been published by Lomakina V et al. J Pharm Pract 2022.

 

Clinical Outcome

No unwanted outcome

Editorial Comment

The product labels for apixaban do not recommend the concomitant use with strong dual CYP3A4 and P-gp inhibitors, although the US label for apixaban gives the option to use apixaban at a reduced dose (i.e., 2.5 mg) if needed.

This case is consistent with previous observations in six HIV infected patients who were successfully treated a reduced dose of apixaban while on ritonavir boosted regimens (Nisly SA et al. Int J STD AIDS 2019).

University of Liverpool Recommendation

These drugs should not be coadministered
For more information click here